FDA Update: Kadcyla approved and more drug news

Share this content:

The new therapy Kadcyla (ado-trastuzumab emtansine) has been approved under the FDA's priority review program for use in persons with HER2-positive, metastatic breast cancer who previously received the anti-HER2 therapy trastuzumab and taxanes. 

The FDA has expanded the approved use of Stivarga (regorafenib) to the treatment of advanced gastrointestinal stromal tumors (GIST) that cannot be resected or that have metastasized and no longer respond to imatinib or sunitinib

Pomalidomide (Pomalyst) is approved by the FDA for the treatment of advanced multiple myeloma in persons who received at least two prior therapies and have demonstrated disease progression on or within 60 days of completion of the last therapy. Pomalidomide is contraindicated during pregnancy and can cause blood clots.

Lymphoseek (technetium Tc99m tilmanocept) Injection, a radioactive diagnostic imaging agent, has been approved by the FDA to help clinicians locate lymph nodes in persons with breast cancer or melanoma who are undergoing surgery to remove tumor-draining lymph nodes. 

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs